Alphanate sd/ht (DrugBank: -)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
288 | 自己免疫性後天性凝固因子欠乏症[自己免疫性出血病XIII (~2017.3)] | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00555555 (ClinicalTrials.gov) | September 2007 | 7/11/2007 | Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients | A Post-marketing Observation Study to Assess the Efficacy and Safety of the FVIII/VWF Complex (Human,) Alphanate(R), in Preventing Excessive Bleeding During Surgery in Subjects With Congenital Type 3 Von Willebrand Disease | Von Willebrand Disease | Biological: Alphanate SD/HT | Grifols Biologicals, LLC | NULL | Active, not recruiting | 7 Years | N/A | All | 15 | Phase 4 | United States |